Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Current Assets for 8 consecutive years, with $51.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 53.22% to $51.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $51.7 million, a 53.22% decrease, with the full-year FY2024 number at $95.0 million, down 30.34% from a year prior.
  • Current Assets was $51.7 million for Q3 2025 at Precision Biosciences, down from $70.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $247.7 million in Q2 2022 to a low of $51.7 million in Q3 2025.
  • A 5-year average of $151.2 million and a median of $147.9 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 53.23% in 2021, then plummeted 53.22% in 2025.
  • Precision Biosciences' Current Assets stood at $161.8 million in 2021, then increased by 23.09% to $199.1 million in 2022, then tumbled by 31.51% to $136.4 million in 2023, then crashed by 30.34% to $95.0 million in 2024, then plummeted by 45.57% to $51.7 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Current Assets are $51.7 million (Q3 2025), $70.3 million (Q2 2025), and $82.1 million (Q1 2025).